Recombinant Human CD40 Ligand/TNFSF5 (108-261), Animal-Free (1 MG)
货号：
AFL617 基本售价：
40600.0 元 规格：
1 mg
产品信息
概述| 货号 | AFL617 |
| 别名 | CD154 antigen; CD154; CD40 antigen ligand; CD40 ligand; CD40-L; CD40LG; CD40LIGM; gp39; hCD40L; HIGM1; T-B cell-activating molecule; T-BAM; T-cell antigen Gp39; TNF-related activation protein; TNFSF5; TNFSF5IMD3; TRAP; TRAPtumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome); tumor necrosis factor (ligand) superfamily member 5; Tumor necrosis factor ligand superfamily member 5 |
| 反应种属 | Human |
| 来源 | E. coli-derived Glu108-Leu261, with an N-terminal Met Produced using non-animal reagents in an animal-free laboratory. |
| 产品组分 | |
性能| 供应商 | R&D Systems |
| Entrez Gene IDs | 959 (Human); 21947 (Mouse); 84349 (Rat) |
| 内毒素水平 | <0.10 EU per 1 μg of the protein by the LAL method. |
| 生物活性 | Measured in a cell proliferation assay using B cell-enriched peripheral blood mononuclear cells (PBMC) in the presence of IL-4. Spriggs, M.K. et al. (1992) J. Exp. Med. 176:1543. The ED50 for this effect is typically 1‑3 µg/mL in the presence of 20 ng/mL of recombinant human IL·4. |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | CD40 Ligand, also known as TNFSF5, CD154, TRAP, and gp39, is a trimeric protein that is expressed in transmembrane and soluble forms. It is expressed by many immune cell types as well as by endothelial and smooth muscle cells of the vasculature. It binds to CD40 on antigen presenting cells, platelets, and endothelial and epithelial cells, leading to enhanced B cell activation and T cell dependent humoral immune responses. CD40 Ligand dysregulation contributes to immune pathology in AIDS, atherosclerosis, atherothrombosis, and restenosis. |
| Accession # | P29965 |
| 运输条件 | Blue Ice |
N-terminal
Sequence Analysis | Met |
| 预期分子量 | 16.9 (monomer) kDa |
| SDS-PAGE | 18 kDa, reducing conditions |
| 存放说明 | -20℃ |
| 纯度 | >97%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| 参考文献 | - Zhang, G. (2004) Curr. Opin. Struct. Biol. 14:154.
- Hehlgans, T. and K. Pfeffer (2005) Immunology 115:1.
- Quezada, S.A. et al. (2004) Annu. Rev. Immunol. 22:307.
- Graf, D. et al. (1992) Eur. J. Immunol. 22:3191.
- Hollenbaugh, D. et al. (1992) EMBO J. 11:4313.
- Khandekar, S.S. et al. (2001) Protein Expr. Purif. 23:301.
- Pietravalle, F. et al. (1996) J. Biol. Chem. 271:5965.
- Garber, E. et al. (1999) J. Biol. Chem. 274:33545.
- Vakkalanka, R.K. et al. (1999) Arthritis Rheum. 42:871.
- van Kooten, C. and J. Banchereau (1997) Curr. Opin. Immunol. 9:330.
- Eissner, G. et al. (2004) Cytokine Growth Factor. Rev. 15:353.
- Rickert, R.C. et al. (2011) Immunol. Rev. 244:115.
- Elgueta, R. et al. (2009) Immunol. Rev. 229:152.
- Kornbluth, R.S. (2000) J. Leukoc. Biol.68:373.
- Chougnet, C. (2003) J. Leukoc. Biol. 74:702.
- Pamukcu, B. et al. (2011) Ann. Med. 43:331.
- Hassan, G.S. et al. (2012) Immunobiology 217:521.
|
